Clinical Observation On The Treatment Of Postmenopausal Osteoporosis With Teriparatide

Objective: to observe the clinical use and efficacy of teriparatide in the treatment of postmenopausal osteoporosis.Methods: A retrospective analysis was conducted from March 2014 to November2017,and a total of 71 cases of postmenopausal osteoporosis were treated with teriparatide in the first hospital affiliated to suzhou university,and the clinical use of teriparatide in all patients was statistically analyzed.All patients were followed up by telephone for the use of time and reasons for discontinuation.Statistics all of the patients before treatment and after treatment for 3 months,6 months after treatment of the lumbar spine(L2-4),femoral neck,and all hip bone mineral density(BMD),beta collagen cross-linked C-terminal peptide(?-CTX)and N terminal propeptide of type I procollagen(TP1NP),and osteoporosis VAS pain score.The changes of bone mineral density,bone metabolism markers and VAS score before and after treatment were observed and compared.Results: 31 cases were treated more than 12 months,17 cases were treated more than6 months and less than 12 months,19 cases were treated more than 3 months and less than6 months,and 4 cases were treated less than 3 months.Common reasons for the withdrawal include: no significant effect,adverse reactions and high expense,accounting for 17.5%,12.5% and 10% respectively.At 3 months,6 months and 12 months,the lumbar BMD increased by 2.7%,9.5%(P<0.05)and 15.5%(P<0.05).The BMD of neck of femur increased by 1.6%,4.8% and 5.1% respectively,and the BMD of all hip joints increased by1.4%,2.8% and 10.6%(P<0.05)respectively.At 3 months,6 months and 12 months,beta collagen cross-linked C-terminal peptide(?-CTX)increased by 20.0%(P<0.05),18.6%(P<0.05)and 1.1%,and N terminal propeptide of type I procollagen(TP1NP)increased by67.7%(P<0.05),99.3%(P<0.05)and 155.2%(P< 0.05).The VAS score decreased by61.5%(P<0.05),70.7%(P<0.05)and 77.6%(P<0.05)respectively.Conclusion: Pain relief and the elevation of bone formation makers can be improvedsignificantly after Teriparatide treatment for 3 months in postmenopausal osteoporosis.Lumbar vertebral density increased significantly after 6 months of Teriparatide treatment.The total bone density of the hip joint was increased after 12 months.Moreover,the efficacy of teriparatide was significantly increased with the duration of medication.